A Phase 1 Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2016
At a glance
- Drugs X4P 001 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors X4 Pharmaceuticals
- 01 Aug 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2016 Status changed from planning to recruiting.